When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 19 Sep 2025
Last updated: 14 Mar 2025

Summary

Your Organisational Guidance

ebpracticenet urges you to prioritise the following organisational guidance:

Richtlijn zorg voor patiënten met hiv in de eerste lijnPublished by: Werkgroep Ontwikkeling Richtlijnen Eerste Lijn (Worel)Last published: 2023GPC sur la prise en charge des patients vivant avec le VIHPublished by: Groupe de Travail Développement de recommmandations de première ligneLast published: 2023

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • fevers and night sweats
  • weight loss
  • skin rashes and post-inflammatory scars
  • oral ulcers, angular cheilitis, oral thrush, or oral hairy leukoplakia
  • diarrhoea
  • changes in mental status or neuropsychiatric function
  • recent hospital admissions
  • tuberculosis (TB)
  • medical comorbidities
  • generalised lymphadenopathy
  • genital sexually transmitted infections (STIs)
  • chronic vaginal candidiasis
  • shingles
  • wasting syndrome
  • headaches
  • Kaposi's sarcoma
  • periodontal disease
  • retinal lesions on fundoscopy
  • shortness of breath on exertion, cyanosis on exertion, dry cough, silent chest on auscultation

Other diagnostic factors

  • peripheral neuropathy
  • recurrent herpes simplex
  • hepatomegaly or splenomegaly
  • meningeal signs (bacterial or viral meningitis)

Risk factors

  • unprotected anal intercourse
  • unprotected penile-vaginal sexual intercourse
  • gay men and other men who have sex with men (MSM)
  • transgender people
  • commercial sex worker
  • people who inject drugs
  • coinfection with other sexually transmitted infections (STIs)
  • people living in prisons
  • percutaneous needle stick injury
  • racial and ethnic minorities
  • use of progestin-only injectable contraceptives
  • cosmetic injection procedures

Diagnostic investigations

1st investigations to order

  • fourth-generation antigen/antibody enzyme-linked immunosorbent assay (ELISA)
  • HIV-1/HIV-2 antibody differentiation immunoassay
  • HIV nucleic acid test
  • CD4 count
  • serum viral load (HIV RNA)
  • drug resistance testing
  • pregnancy test
  • serum hepatitis B serology
  • serum hepatitis C serology
  • hepatitis A serology (IgG)
  • toxoplasma serology (IgG)
  • FBC with differential
  • basic metabolic panel
  • urinalysis
  • liver function tests (LFTs)
  • random or fasting plasma glucose
  • lipid profile
  • human leukocyte antigen-B*5701 testing
  • testing for sexually transmitted infections (STIs) including mpox

Investigations to consider

  • chest x-ray
  • testing for tuberculosis
  • testing for cryptococcosis

Treatment algorithm

Contributors

Authors

Chad J. Achenbach, MD, MPH

Professor of Medicine, Preventive Medicine, and Biomedical Engineering

Infectious Diseases

Northwestern Medicine

Feinberg School of Medicine

McCormick School of Engineering

Northwestern University

Evanston and Chicago

IL

Disclosures

CJA declares that he has no competing interests.

Acknowledgements

Dr Chad J. Achenbach would like to gratefully acknowledge Dr Richard Rothman, Dr Michael Ehmann, Dr Linda-Gail Bekker, Dr Catherine Orrell, and Dr Lisa Capaldini, the previous contributors to this topic.

Disclosures

ME, LGB, and CO declare that they have no competing interests. RR attended a symposium/conference hosted by a funding agency, Gilead HIV FOCUS programme, from which he receives research funds. RR pays staff for an implementation/research programme grant from Gilead HIV FOCUS for development of HIV testing programmes in Emergency Departments. LC is on the speakers' bureau for the following pharmaceutical companies: GlaxoSmithKline, BMS, Merck, Gilead, Roche, Pfizer, Solvay, Lilly, Serrano, and Tibotec.

Peer reviewers

Michael Horberg, MD, MAS, FACP, FIDSA

Associate Medical Director

Kaiser Permanente Mid-Atlantic Permanente Medical Group

Oakland

CA

Disclosures

MH declares that he has no competing interests

Roy Gulick, MD

Professor of Medicine

Chief of the Division of Infectious Diseases

Weill Cornell Medicine

New York

NY

Disclosures

RG declares that he has no competing interests

Marianne Harris, MD

Clinical Assistant Professor

University of British Columbia

Vancouver

Canada

Disclosures

MH is a member of an advisory board and/or speakers' bureau for Gilead Sciences Canada Inc, Merck Canada Inc, and ViiV Healthcare.

Jeremy Day, BChir, MB

Infectious Disease Physician

Oxford University Clinical Research Unit

Hospital for Tropical Diseases

Ho Chi Minh City

Vietnam

Disclosures

JD declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Sep 2015 [internet publication].Full text

US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Sep 2024 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer